Synbio: The Next Big Thing in Biotech

Trading the Next Phase of COVID-19 Variants

By

|

More than a year after the start of the COVID-19 pandemic, new variants of the disease pose a threat to those unvaccinated—which is more than 70% of the world. Few would have predicted that the world would still be grappling with the COVID-19 pandemic during the summer of 2021. Yet here we are. And unfortunately, … Continued

10 Charts That Define 2020’s Trading and What That Means for 2021 (Yes, There Is a Tesla Chart)

By

|

The 2020 trading year saw record volatility, record highs, record lows, and everything in between—as illustrated in the charts below. From a trading and investment perspective, 2020 has been one of the most memorable in history.  Today’s post represents a year in review in chart form—ideal for any market participant reflecting on the year that … Continued

Vaccines + (AZN + ALXN) = Booming Biotech

By

|

Valuations in the biotechnology sector received a boost on Dec. 12 when AstraZeneca (AZN) announced it would pay a 45% premium for Alexion Pharmaceuticals (ALXN), a stock that had already rallied 47% since mid-March. On Dec. 11, the Food & Drug Administration (FDA) made history when it approved the first COVID-19 vaccine for use by … Continued

Remdesivir: Confidence or Confusion?

By

|

Critical COVID-19 Treatment Update The global effort to discover safe and effective treatments for COVID-19 suffered a significant setback late last week when the World Health Organization (WHO) released its assessment of Remdesivir—a drug previously authorized in the United States for emergency use—suggesting that the drug provides little benefit for severely ill COVID-19 patients. The … Continued